EGFR exon 19 deletion

ASCO 2023 Plenary abstract LBA3 Dr Roy Herbst lead author of the ADAURA study in EGFRm (ex19del/L858R) stage IB, II or IIIA NSCLC; overall survival benefit of 51% reduction in risk of death in the overall population. #ASCO2023 #precisiononcology #PoetOncology #targetedtreatment (@POETOncology)

Dear professor,i sent you a DM for my mom.She has NSCLCadeno with bone mets a rare EGFR exon19 del E756T751 can you please check (@merttopraakkk)

3/ 📌 On Dec 18, 2020, the @FDAOncology gave a thumbs up 👍 to osimertinib for adjuvant therapy post tumor resection in NSCLC patients with EGFR exon 19 deletions or exon 21 L858R mutations. ADAURA study showed ➡️ Median DFS not reached vs 19.6 months on placebo (HR 0.17,… https://t.co/zLg1uyLDCc (@ADesaiMD)

NSCLC with an #EGFR exon 20 insertion mutation is different from exon 19 deletion and exon 21 L858R! Drs. Byoung-Chul Cho and @charocampelo describe their approach and Marcia Horn @Exon20Group provides perspective in this episode of #LungCancerConsidered https://t.co/i16OujxoC7 (@StephenVLiu)

Real-world cohort analysis of EGFR+ lung cancer transformed into SCLC reveals APOBEC mutations & seen more commonly in EGFR exon19del variants. Histologic transformation now documented in several oncogene-addicted lung cancers. @christine_lovly @VanderbiltU #SCLC23 @EGFRResisters (@LUNGevity)

🆕in @CCR_AACR an analysis investigating the efficacy of Osi in pts with lung cancer harbouring *uncommon* EGFR exon 19 del mut’s E746_A750del was associated with significantly prolonged mPFS with 1L Osi vs. L747_A750>P (21.3 vs. 11.7m; [HR] 0.52 ; p=0.043). Understanding… https://t.co/LkXdWa0p8E (@APassaroMD)

Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations https://t.co/1PQ124GUBu (@AndresFCardonaZ)

2/ @LeXiuning @MDAndersonNews on EGFR mutations: ▪️EGFR mutations ~10-20% NSCLC pts in Europe/N America, & up to 50% of patients in Asia ▪️Exon 19 del & exon 21 L858R most common (~85-90%) ▪️🔑 Most frequent uncommon mutations to know: G719X, S768I, L861Q, & exon 20 insertions (@esinghimd)

🦄 Osimertinib in non-exon 19 deletion or L858R EGFR mutations (excluded from FLAURA trial) Important issue, as they represent ≈ 20% of EGFR mutations in the clinic. Thrilled to participate in this study now @IASLC 🔝 as Editor’s choice @JTOonline #LCSM https://t.co/adB3FJKezV (@Tony_Calles)

Hey #lcsm precision onc guru friends- you want to be an Alkemist and help w challenging case? Young pt w egfr ex19 del, nice response to osi for yr+, now progression incl CNS CNS specimen now shows STRN-ALK fusion along w ex19del. Getting SRS to resid CNS dx What is best syst tx? (@DrSteveMartin)

My fellow #3MusketeersforLCSM presents a very interesting case on “Concomitant EGFR exon 19 deletion and ERBB2 mutation in a patient with metastatic non-small cell lung cancer” #EGFRSummit22 #lcsm @EGFRSummit @EGFRResisters (@esinghimd)

Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group https://t.co/feIIxBSq30 (@mlazqui)

Nice talk on EGFR (it’s not enough to just name the street anymore, you have to say the whole address- exon 19 del, exon 20 insertion, L858R etc) in mNSCLC by ⁦@MdCurioni⁩ ⁦@LungSummit⁩ (@PatelOncology)

Using computational & experimental models in a study funded by our division, @MeilerLab, @christine_lovly, et al. revealed allele-specific activation, enzyme kinetics, & inhibitor sensitivities of EGFR exon 19 deletion mutations in #lungcancer @PNASNews https://t.co/Q2BVXBA8r6. (@NCICancerBio)

During a live virtual event, Benjamin P. Levy, MD, discussed the case of a patient with non–small cell lung cancer and an EGFR exon 19 deletion. This is the second of two articles based on this event. #NSCLC #lcsm | @benlevylungdoc @KimmelCancerCtr https://t.co/VfOEuk5tv8 (@TargetedOnc)

🧵11 We analyze a large cohort (n=121) of putative tSCLC w/ driver mut typically found in NSCLC ➡️EGFR (ex19del > L858R in SCLC cases!) ➡️ALK ➡️ROS1 ➡️RET ➡️NTRK Need for rebiopsy of all driver+ NSCLC to look for SCLC @EGFRResisters @ALKLungCancer @ros1cancer @RetRenegades (@christine_lovly)

I'm very excited to share our recent PNAS paper with the Lovly and Meiler groups!! @christine_lovly @MeilerLab Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. https://t.co/oLL0mj37Ha (@awsmith)

67, f, right upper lobe lobectomy, pT2aN1M0 adenocarcinoma harboring an EGFR exon 19 deletion and PDL1 10%. next step? 1. cis/pem x4; 2 cis/pemx4 erlotinibx2y 3. cis/pemetrexedx4 Osix 2 y 4. cis/ pemx4 durvalumab x1y. From ASCO SEP DIGITAL qBANK #lungcancer (@wangyub)

AENEAS: Randomized 1L Phase III Trial of Aumolertinib Vs. Gefitinib in Met. NSCLC With EGFR Ex 19 Deletion/L858R Mut | ⁦⁦@JCO_ASCO⁩ I can’t keep up with all new EGFRi! ⁦⁦@NarjustDumaMD⁩ ⁦@DrMarkAwad⁩ ⁦⁦@CharuAggarwalMD⁩ https://t.co/q4IroZuBe9 (@DrChoueiri)

⭐️ Another new drug for EGFR ✅AUMOLERTINIB 👉🏼AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as 1st-Line Therapy for Locally Advanced or Metastatic NSCLC With EGFR Exon 19 Deletion or L858R Mutations 🧬🎯@JCO_ASCO @OncoAlert https://t.co/ko2T8sUFLh (@VivekSubbiah)

First-line FDA-approved therapies for EGFR-sensitizing mutations like exon 19 deletions include osimertinib as the preferred frontline treatment, followed by erlotinib, gefitini, afatinib, and dacomitinib @ZPiotrowskaMD @MassGeneralNews #lcsm https://t.co/h29AI609Uz (@OncLive)

#TTLC22 Dr. @MJGrantMD presents outcomes with a specific subset of #EGFR exon 19 deletion NSCLC: L747-A750>P. Accounts for ~4% of del19. The proline insertion subset had a worse prognosis. Potential role for afatinib in this subset? Preclinical support; needs clinical validation. (@StephenVLiu)

In most #EGFR NSCLC studies, exon 19 deletion associated with better outcomes than exon 21 L858R. This single center analysis explores co-mutations in tumor suppressor genes between the two. Could KEAP1 alterations be playing a role in EGFR mutant NSCLC? https://t.co/FTMW7hF1uV (@StephenVLiu)

#ESMO21 #LCSM Ph2 WJOG9717L trial: osimertinib plus bevacizumab vs Osi for NSCLC with comm EGFR mut’s Subgroup analysis with better trend of PFS for OB: 🔹ex-smoker (HR 0.481) 🔹19del (HR 0.622) ▪️ORR: 82% vs 86% for O arm. 🔸G3/4 AEs: OB 56% vs O 48% for OB arm (@APassaroMD)

#ESMO21 #LCSM Dr Piccirillo presenting thePh3 BEVERLY-trial: Italian random open-label, trial of bevacizumab (BEV) plus erlotinib (E) vs E alone as 1L treat for EGFR-mut a NSCLC. 180 pts random: 80 vs 80 55% of pts had ex19Del and 41% L858R mutation (@APassaroMD)

We have designed this session to be case-based & highly interactive. Hot topics like: “My patient with stage IV NSCLC and PD-L1 of 80% has already been started on checkpoint inhibitor elsewhere. Now molecular testing shows EGFR ex19del. YIKES!! What do I do now? Join us. (@drgandara)